SCHEMBL3557737

SCHEMBL3557737

COc1cc(OC)c(N[C]=O)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
CYP3A4 P08684 5/20 0.41
CYP1A2 P05177 3/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ERN1 O75460 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
CASP3 P42574 1/20 0.38
PAX8 Q06710 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3553661 0.89 FFAR4 (0.42) ALDH1A1CYP3A4CYP1A2CA12CA1
SCHEMBL3555765 0.87 CYP3A4 (0.49) CYP3A4USP2MAPK1SMN1; SMN2ERN1
SCHEMBL3558547 0.83 ACHE (0.46) ALDH1A1CYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL3559775 0.82 CYP3A4 (0.48) CYP3A4CA12CA1CA2CA7
SCHEMBL3555814 0.78 CYP3A4 (0.48) ALDH1A1CYP3A4USP2MAPK1SMN1; SMN2
SCHEMBL2091512 0.77 CA1 (0.44) ALDH1A1CYP3A4CYP1A2CA12CA1
SCHEMBL3557740 0.75 ERN1 (0.47) ALDH1A1CYP3A4CYP1A2CA12CA1
SCHEMBL3192483 0.75 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP1A2CA12CA1
SCHEMBL2203557 0.75 ALDH1A1 (0.56) ALDH1A1CYP1A2CA12CA1CA2
SCHEMBL6560132 0.74 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP1A2SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5502198-A α-aryl or heteroaryl-substituted amide ester ACAT inhibitors WARNER-LAMBERT COMPANY (US) 1996-03-26 US claimed
US-7662826-B2 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD. (JP) 2010-02-16 US disclosed
US-20060089362-A1 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD (JP) 2006-04-27 US disclosed
EP-1505068-A1 PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 2005-02-09 EP disclosed
EP-1155698-A1 ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES Nitto Kasei Co., Ltd. (JP) 2001-11-21 EP disclosed
EP-1057825-A1 ISOFLAVANE DERIVATIVES AND IMMUNOPOTENTIATING COMPOSITIONS CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 2000-12-06 EP disclosed
US-5502198-A α-aryl or heteroaryl-substituted amide ester ACAT inhibitors WARNER-LAMBERT COMPANY (US) 1996-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089362-A1 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same NADK, PNPO, NQO1 ALDH1A1 85/4885CYP3A4 300/4885CYP1A2 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.